These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Rice GP; Filippi M; Comi G Neurology; 2000 Mar; 54(5):1145-55. PubMed ID: 10720289 [TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Selby R; Brandwein J; O'Connor P Can J Neurol Sci; 1998 Nov; 25(4):295-9. PubMed ID: 9827230 [TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Romine JS; Sipe JC; Koziol JA; Zyroff J; Beutler E Proc Assoc Am Physicians; 1999; 111(1):35-44. PubMed ID: 9893155 [TBL] [Abstract][Full Text] [Related]
8. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617 [No Abstract] [Full Text] [Related]
9. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M; Grieb P Mult Scler; 2009 Jun; 15(6):767-70. PubMed ID: 19482866 [TBL] [Abstract][Full Text] [Related]
11. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Janiec K; Wajgt A; Kondera-Anasz Z Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501 [TBL] [Abstract][Full Text] [Related]
12. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743 [TBL] [Abstract][Full Text] [Related]
13. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis]. Oreja-Guevara C; García-Merino JA; Saiz A; Rodríguez-Antigüedad A; Álvarez-Cermeño JC; Estrada-Pérez V; Izquierdo G; Fernández O Rev Neurol; 2019 Dec; 69(s02):1-9. PubMed ID: 31933293 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107 [TBL] [Abstract][Full Text] [Related]
15. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049 [TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
20. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M; Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]